Lupin
LUPIN · Pharma > Pharmaceuticals & Drugs · Chairman: Manju D Gupta · MD: Nilesh Gupta · Listing date: Sept. 11, 2001 · Employees: 18573 · Mumbai · http://www.lupin.com

Stock Price vs Company Growth
1d
1.3%
1w
2.0%
1m
1.2%
3m
0.3%
6m
8.6%
1y
6.3%
5y
17.2%
10y
0.3%
all
16.8%

Use @ for users, # for companies and : for emojis
 
 
 
 
Last Traded Price

₹ 1,930 1.3%
1,876
2,149
Company Overview

Sales
22,708 Cr
Growth: 12.5%
Profit after Tax
3,282 Cr
Growth: 14.4%
Large Cap
88,157 Cr
P/E: 27.2x
Industry P/E: 33.3x
Fundamentals

Sales (Cr) ₹ 22,708
Growth 12.5%
EBITDA 23.2%
P/S 3.9x
Dividend 0.4%
P/E 27.2x
Book Value ₹ 377
PEG Ratio 2.2x
ROE 20.2%
P/B 5.2x
Shareholding Pattern

Institutions
Life Insurance Corporation Of India
6.99 %
Hdfc Trustee Company Limited-Hdfc Flexi Cap Fund
4.28 %
Government Pension Fund Global
1.21 %
Franklin India Focused Equity Fund
1.13 %
Icici Prudential Life Insurance Company Limited
1.13 %
Promoters
Lupin Investments Pvt Ltd
45.3 %
Manju D Gupta
0.85 %
Nilesh D Gupta
0.2 %
Anuja Gupta
0.16 %
Desh Bandhu Gupta Huf
0.14 %
Others
Rakesh Jhunjhunwala
1.6 %
Nps Trust - A/C Lic Pension Fund Sch-State Govt
1.48 %
Iepf
0.15 %
Increase    Decrease    No change
Company Profile Detailed

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India.Products and services offered by the companyGlobal FormulationsActive Pharmaceuticals Ingredients (API)BiotechSpecialty BusinessOver The Counter (OTC)Global Manufacturing & Supply ChainAwards2007: Cardinal Health Conferred Two Awards - The ‘Trade Representative Of The Year’ And The ‘Quality Supplier Award’ To Lupin Pharmaceuticals Inc.
Investors (232)
Followers (56)